“The Addition of Blinatumomab to Chemotherapy Proves Safe and Effective in Phase II Study for Infants with Aggressive Acute Lymphoblastic Leukemia (ALL): New England Journal of Medicine Publishes Promising Results”

2023-05-03 15:00:05

The addition of blinatumomab to chemotherapy has been shown to be safe and effective in a phase II study in infants with aggressive acute lymphoblastic leukemia (ALL). The results have now been published in the prestigious New England Journal of Medicine published.

grandriver – GettyImages

In the past, it has proven particularly difficult to treat infants with ALL. Disease-free survival rates and overall survival rates were much lower than in older children. A combination therapy with the CD19 antibody blinatumomab now gives new hope.

To see the content you need to log in or register.